GlobeStar Therapeutics Corporation
GSTC · OTC
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $193 | $168 | $156 | $288 |
| SG&A Expenses | $193 | $168 | $156 | $288 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $193 | $168 | $156 | $288 |
| Operating Income | -$193 | -$168 | -$156 | -$288 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$4 | -$7 | -$8 | -$63 |
| Pre-Tax Income | -$198 | -$175 | -$164 | -$351 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$198 | -$175 | -$164 | -$351 |
| % Margin | – | – | – | – |
| EPS | -0 | -0 | -0 | -0 |
| % Growth | 0% | 0% | 50% | – |
| EPS Diluted | -0 | -0 | -0 | -0 |
| Weighted Avg Shares Out | 1,208,972 | 1,127,084 | 1,004,028 | 939,876 |
| Weighted Avg Shares Out Dil | 1,208,972 | 1,127,084 | 1,004,028 | 937,629 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $4 | $7 | $8 | $63 |
| Depreciation & Amortization | $193 | $0 | $0 | -$7 |
| EBITDA | $0 | -$168 | -$156 | -$288 |
| % Margin | – | – | – | – |